Downloads provided by UsageCountsAutoantibodies against type I IFNs in patients with critical influenza pneumonia
Copyright policy )EC| UNDINE ,
ANR| GenMIS-C ,
NIH| Inborn errors of immunity in children with herpes simplex encephalitis ,
HFRI| unidentified ,
NIH| Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success ,
NIH| Modulation of Lung Immune Responses to Viral Infection ,
NIH| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) ,
EC| EASI-Genomics ,
NIH| Fluomics: The Next Generation ,
NIH| Inborn errors of immunity in patients with life-threatening COVID-19 ,
NIH| Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19 ,
NIH| Inborn errors of immunity in patients with life-threatening COVID-19
Zhang, Qian; Pizzorno, Andrés; Miorin, Lisa; Bastard, Paul; Gervais, Adrian; Le Voyer, Tom; Bizien, Lucy; +193 Authors
Zhang, Qian; Pizzorno, Andrés; Miorin, Lisa; Bastard, Paul; Gervais, Adrian; Le Voyer, Tom; Bizien, Lucy; Manry, Jeremy; Rosain, Jérémie; Philippot, Quentin; Goavec, Kelian; Condino-neto, Antonio; Dominguez Pinilla, Nerea; Meyts, Isabelle; Aydillo, Teresa; Okamoto, Keisuke; Anderson, Mark S.; Soumaré, Aïcha; Wroblewski, Isabelle; Karamitros, Timokratis; Ruiz Hernandez, José Juan; Covid Human Genetic Effort; Medina, Rafael A.; Kisand, Kai; Ramírez Duque, Nieves; Feys, Simon; Romero Oraa, Laura; Kuo, Chen-yen; Lei, Wei-te; Resnick, Igor; Quintana Murci, Lluis; Milner, Joshua D.; Rombauts, Alexander; Jeanne, Michel; García Salum, Tamara; Ku, Cheng-lung; Van De Beek, Diederik; Hsieh, Elena W.Y.; Tal, Galit; Fournet, Thomas; Cerba Healthcare Group; Patural, Hugues; Pesole, Graziano; Zatz, Mayana; Novelli, Giuseppe; Morio, Tomohiro; Lyon Antigrippe Working Group; Arias, Andrés A.; Shahrooei, Mohammed; Rovina, Nikoletta; Rodríguez-Gallego, Carlos; Puel, Anne; Jouanguy, Emmanuelle; Vinh, Donald C.; Uddin, K.m. Furkan; Abel, Laurent; Su, Helen C.; Bonneaudeau, Brigitte; Henny, Joseph; Mogensen, Trine H.; Cobat, Aurélie; Casari, Giorgio; Slaby, Ondrej; Ramaswamy, Sathishkumar; Abelenda Alonso, Gabriela; Kisand, Kai; Morel, Pascal; Fragkou, Paraskevi C.; Argaud, Laurent; Cannet, Dorothée; Vanderbeke, Lore; Belot, Alexandre; Shcherbina, Anna; Al-muhsen, Saleh; Biggs, Catherine M.; Bogunovic, Dusan; Gallian, Pierre; Husebye, Eystein; Planas, Anna M.; Heath, James R.; Von Bernuth, Horst; Ku, Cheng-lung; Dufouil, Carole; Hagin, David; Bolze, Alexandre; Etablissement Français Du Sang Study Group; Froidure, Antoine; Fievet, Nathalie; Laurent, Emilie; Galani, Ioanna Evdokia; Pothier, Pierre; Gregersen, Peter K.; Lemonnier, Sylvie; Padey, Blandine; Carratalà, Jordi; Spaan, András N.; Darmon, Michael; Grimbacher, Bodo; Palomo, Virginia; Del Mar Muñoz Garcia, Maria; Zawadzki, Pawel; Henrickson, Sarah E.; Haerynck, Filomeen; O'farrelly, Cliona; Morand, Patrice; Niubó, Jordi; Rosa Calatrava, Manuel; Trouillet Assant, Sophie; Lachaize, Morgane; Jarvis, Erich D.; Okada, Satoshi; Vanker, Martti; Bryceson, Yenan; Ling, Yun; Cooper, Megan A.; Lucas, Carrie L.; Maniatis, Tom; Gallardo Ríos, Rafaela; Romero Vázquez, Gloria María; Navarrete, Nicolás; Richard, Pascale; Desai, Murkesh; Mansouri, Davood; Castagnoli, Riccardo; Zins, Marie; Maródi, László; Mironska, Kristina; Rapti, Vasiliki; Baris Feldman, Hagit; Lau, Yu-lung; Pozzetto, Bruno; Boeuf, Benoit; Renia, Laurent; Tancevski, Ivan; Ferres, Marcela; Franco, José Luis; Imai, Kohsuke; Ozcelik, Tayfun; Pan-Hammarström, Qiang; Al-mulla, Fahd; Pape, Jean W.; Triantafyllia, Vasiliki; Rodríguez de Castro, Felipe; Etzioni, Amos; Souweine, Bertrand; Pérez de Diego, Rebeca; Wauters, Joost; Sánchez Céspedes, Javier; Sánchez Cordero, Maria Jose; Uddin, Mohammed J.; Solé Violán, Jordi; Perroquin, Magali; Ng, Lisa F.P.; Ferreres, José; Briones, Marisa; Abou Tayoun, Ahmad; Le Corre, Nicole; Snow, Andrew L.; Temel, Şehime Gülsün; Tsiodras, Sotirios; Tzourio, Christophe; Merino Díaz, Laura; Coeuret Pellicer, Mireille; Notarangelo, Luigi D.; Flaig, Amandine; Javouhey, Etienne; Saker, Kahina; Turvey, Stuart E.; Pujol, Aurora, 1968-; Cognasse, Fabrice; Sancho Shimizu, Vanessa; Tiberghien, Pierre; Reipi Inf Working Group; Nadif, Rachel; Hanna, Suhair; Rodríguez Gallego, Carlos; Flores, Carlos; Seppänen, Mikko R.J.; Constances Cohort; Goldberg, Marcel; Brodin, Petter; Andreakos, Evangelos; Le Got, Stéphane; Ozguler, Anna; Quenot, Jean Pierre; García Sastre, Adolfo; Christodoulou, John; Novelli, Antonio; Perlin, David S.; Cordero, Elisa; Colomb, Benoit; Särekannu, Karita; Cupic, Anastasija; Mehlal Sedkaoui, Souad; Sallette, Jérôme; Hernu, Romain; Bustamante, Carlos D.; Bondarenko, Anastasiia; Lina, Bruno; Constantinescu, Stefan N.;
Autoantibodies against type I IFNs in patients with critical influenza pneumonia
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
Belgium, Italy, Turkey, France, Belgium, Spain, Spain, Spain, Italy, Chile, Italy
Informe de Investigación, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Virus de la Influenza A, SEVERE COVID-19, Pneumònia, DETERMINANTS, Autoanticossos, Research & Experimental Medicine, Settore MED/03 - GENETICA MEDICA, Virus Replication, 3C-Dijon Study, 03 Salud y bienestar, INFECTION, Medicine and Health Sciences, Prevalence, MYASTHENIA-GRAVIS PATIENTS, 11 Medical and Health Sciences, REIPI INF Working Group, ERN-RITA, Yellow Fever Vaccine, Autoanticuerpos, Jeffrey Modell Foundation, Medicine, Research & Experimental, Influenza A virus, Influenza Vaccines, Interferon Type I, [SDV.IMM]Life Sciences [q-bio]/Immunology, BURDEN, Constances Cohort, Life Sciences & Biomedicine, INTERFERON, Cerba HealthCare Group, Anticuerpos, [SDV.IMM] Life Sciences [q-bio]/Immunology, SARS-Cov-2, Immunology, 610, IMMUNITY, Antibodies, Article, NEUTRALIZING ANTIBODIES, Grip, Vacuna contra la Fiebre Amarilla, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 616, Neumonía, Influenza, Human, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Type I interferons, Gripe Humana, Interferón Tipo I, Humans, COVID Human Genetic Effort, 320505 Enfermedades infecciosas, Autoantibodies, Células A549, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Science & Technology, Etablissement Français du Sang Study Group, 42 Health sciences, COVID-19, 32 Biomedical and clinical sciences, Pneumonia, ALLELES, Lyon Antigrippe Working Group, Influenza, ALPHA, A549 Cells, 03 Good Health and Well-being, 32 Ciencias médicas
Informe de Investigación, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Virus de la Influenza A, SEVERE COVID-19, Pneumònia, DETERMINANTS, Autoanticossos, Research & Experimental Medicine, Settore MED/03 - GENETICA MEDICA, Virus Replication, 3C-Dijon Study, 03 Salud y bienestar, INFECTION, Medicine and Health Sciences, Prevalence, MYASTHENIA-GRAVIS PATIENTS, 11 Medical and Health Sciences, REIPI INF Working Group, ERN-RITA, Yellow Fever Vaccine, Autoanticuerpos, Jeffrey Modell Foundation, Medicine, Research & Experimental, Influenza A virus, Influenza Vaccines, Interferon Type I, [SDV.IMM]Life Sciences [q-bio]/Immunology, BURDEN, Constances Cohort, Life Sciences & Biomedicine, INTERFERON, Cerba HealthCare Group, Anticuerpos, [SDV.IMM] Life Sciences [q-bio]/Immunology, SARS-Cov-2, Immunology, 610, IMMUNITY, Antibodies, Article, NEUTRALIZING ANTIBODIES, Grip, Vacuna contra la Fiebre Amarilla, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 616, Neumonía, Influenza, Human, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Type I interferons, Gripe Humana, Interferón Tipo I, Humans, COVID Human Genetic Effort, 320505 Enfermedades infecciosas, Autoantibodies, Células A549, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Science & Technology, Etablissement Français du Sang Study Group, 42 Health sciences, COVID-19, 32 Biomedical and clinical sciences, Pneumonia, ALLELES, Lyon Antigrippe Working Group, Influenza, ALPHA, A549 Cells, 03 Good Health and Well-being, 32 Ciencias médicas
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).110 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1% views 191 downloads 303 - 191views303downloads
selected citations
Citations provided by BIP!
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP!influenceInfluence provided by BIP!
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Influence provided by BIP!impulseImpulse provided by BIP!
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
Impulse provided by BIP!viewsViews provided by UsageCounts
Views provided by UsageCountsdownloadsDownloads provided by UsageCounts
Downloads provided by UsageCounts 110
Top 1%
Top 10%
Top 1%
191
303
Green
hybrid
